Clinical trials: Lenalidomide
Multiple Myeloma
Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
The purpose of this Phase II study is to evaluate the safety and effectiveness (good and bad effects) of carfilzomib given as a 30-minute infusion and at a dose of 70 mg/m2 to treat patients with multiple myeloma (MM), who are…
- Trial name
- NCT02294357
- Testing
- Carfilzomib, Dexamethasone, Prednisone
- Where
- 7 sites in United States
- Volunteers
- 45 people
- Sponsor
- Oncotherapeutics
Multiple Myeloma
MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
The purpose of this study is to determine the Recommended Phase 2 Dose and clinical benefit of elranatamab in combination with other anti-cancer therapies in participants with multiple myeloma.
- Trial name
- NCT05090566
- Testing
- Elranatamab + Nirogacestat, Elranatamab + lenalidomide + dexamethasone
- Where
- 25 sites in United States, Canada
- Volunteers
- 46 people
- Sponsor
- Pfizer
Lymphoma, Follicular
A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
This study will evaluate the safety, efficacy, pharmacokinetics and immunogenicity of induction treatment consisting of atezolizumab in combination with obinutuzumab plus lenalidomide in patients with relapsed or refractory…
- Trial name
- NCT02631577
- Testing
- Atezolizumab (MPDL3280A) [TECENTRIQ], Lenalidomide, Obinutuzumab
- Where
- 16 sites in United States, France
- Volunteers
- 38 people
- Sponsor
- Hoffmann-La Roche
Follicular Lymphoma, Marginal Zone Lymphoma
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during monotherapy and in combination with lenalidomide and/or rituximab in patients…
- Trial name
- SIDNEY (NCT04669171)
- Testing
- EO2463, lenalidomide, rituximab
- Where
- 12 sites in United States, France and 2 more
- Volunteers
- 80 people
- Sponsor
- Enterome
Multiple Myeloma
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
The purpose of the study is to determine whether the addition of Elotuzumab to Lenalidomide/low-dose Dexamethasone will increase the progression free survival (PFS)
- Trial name
- ELOQUENT - 1 (NCT01335399)
- Testing
- Lenalidomide, Dexamethasone, Elotuzumab (BMS-901608; HuLuc63)
- Where
- 235 sites in United States, Australia and 18 more
- Volunteers
- 748 people
- Sponsor
- Bristol-Myers Squibb
Multiple Myeloma
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
The purpose of this study is to evaluate how well (efficacy) cilta-cel works when given with a fludarabine-free lymphodepletion regimen (a process of reducing the number of lymphocytes, a type of white blood cell in the body…
- Trial name
- CARTITUDE-10 (NCT07149857)
- Testing
- Cilta-cel, Cyclophosphamide, Induction therapy
- Where
- 20 sites in United States, Australia and 1 more
- Volunteers
- 60 people
- Sponsor
- Janssen Research & Development, LLC
Myelodysplastic Syndrome
Multi-center, Survival Data Collection in Subjects Previously Enrolled in Celgene Protocol CC-5013-MDS-003
Multi-center, survival data collection in subjects previously enrolled in study NCT00065156 (Celgene Protocol CC-5013-MDS-003).
- Trial name
- NCT01099267
- Where
- 15 sites in United States, Germany
- Volunteers
- 54 people
- Sponsor
- Celgene
Newly Diagnosed Multiple Myeloma
To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma
The goal of this clinical study iMMagine-6 is to compare and assess the safety and effectiveness of anitocabtagene autoleucel versus autologous stem cell transplant in participants with newly diagnosed multiple myeloma (NDMM).
- Trial name
- iMMagine-6 (NCT07903506)
- Testing
- Anitocabtagene Autoleucel, Isatuximab, Bortezomib
- Volunteers
- 750 people
- Sponsor
- Kite, A Gilead Company
Diffuse Large B-Cell Lymphoma
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections).
- Trial name
- EPCORE DLBCL-4 (NCT06508658)
- Testing
- Epcoritamab, Rituximab, Lenalidomide
- Where
- 176 sites in United States, Argentina and 26 more
- Volunteers
- 379 people
- Sponsor
- Genmab
Non Hodgkin Lymphoma
Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL. Part 2: To characterize the activity of acalabrutinib alone or in combination with rituximab in subjects…
- Trial name
- NCT02180711
- Testing
- acalabrutinib, rituximab (IV), Lenalidomide
- Where
- 29 sites in United States, Canada and 1 more
- Volunteers
- 113 people
- Sponsor
- Acerta Pharma BV
Multiple Myeloma
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide…
- Trial name
- MonumenTAL-6 (NCT06208150)
- Testing
- Talquetamab, Pomalidomide, Teclistamab
- Where
- 242 sites in United States, Argentina and 25 more
- Volunteers
- 838 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
A Open-Label Phase in Participants With Multiple Myeloma
This is an open-label, multi-center phase II study of IBI3003 in combination with anti-CD38 monoclonal antibody in adult subjects with multiple myeloma.
- Trial name
- NCT07764861
- Testing
- Dexamethasone, IBI3003, Lenalidomide
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Multiple Myeloma
Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients
The purpose of this clinical research study is to evaluate the safety and effectiveness (good and bad effects) of pomalidomide given as part of a combination therapy that include more than just steroids to treat subjects with…
- Trial name
- NCT02188368
- Testing
- POM, Steroids, PLD
- Where
- 12 sites in United States
- Volunteers
- 45 people
- Sponsor
- Oncotherapeutics
Multiple Myeloma
IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma
The purpose of this study is to provide continued access to ixazomib and/or lenalidomide to participants who are continuing to have clinical benefit and to continue collecting relevant safety data to monitor safety in…
- Trial name
- NCT01850524
- Testing
- Ixazomib, Dexamethasone, Lenalidomide
- Where
- 147 sites in United States, Belgium and 5 more
- Volunteers
- 705 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Newly Diagnosed, Previously Untreated Multiple Myeloma
PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)
The purpose of the study is to look at subjects who receive Lenalidomide, Dexamethasone, and Elotuzumab and determine if they will have lower surface CS1 expression on malignant plasma cells at the time of progression than those…
- Trial name
- NCT01891643
- Testing
- Lenalidomide, Dexamethasone, Elotuzumab
- Where
- 14 sites in United States, Greece and 2 more
- Volunteers
- 23 people
- Sponsor
- Bristol-Myers Squibb
Myelodysplastic Syndromes
Study of CC-5013 to Evaluate Safety, Pharmacokinetics and Effectiveness for Japanese Patients With Symptomatic Anemia Associated With Myelodysplastic Syndrome With a Del(5)(q31-33) Abnormality.
The purpose of this clinical experience study is to determine whether CC-5013 is safe and effective (to include studying the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body…
- Trial name
- NCT00812968
- Testing
- Lenalidomide
- Where
- 6 sites in Japan
- Volunteers
- 11 people
- Sponsor
- Celgene
Multiple Myeloma
A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma
To evaluate the safety and efficacy of lenalidomide with dexamethasone in Japanese patients with previously treated multiple myeloma.
- Trial name
- NCT00928486
- Testing
- Lenalidomide, Dexamethasone
- Where
- 8 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Celgene
Multiple Myeloma
PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma
To assess the safety and tolerability at increasing dose levels of PF-06863135 in patients with relapse/ refractory multiple myeloma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
- Trial name
- NCT03269136
- Testing
- PF-06863135 monotherapy IV or SC, PF-06863135 + dexamethasone, PF-06863135 + lenalidomide
- Where
- 37 sites in United States, Canada
- Volunteers
- 101 people
- Sponsor
- Pfizer
B-Cell Chronic Lymphocytic Leukemia
Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)
The purpose of this study is to determine the safety and efficacy of lenalidomide as a first line therapy in treating patients with B-cell Chronic Lymphocytic Leukemia.
- Trial name
- ORIGIN (NCT00910910)
- Testing
- Lenalidomide, Chlorambucil
- Where
- 165 sites in United States, Australia and 25 more
- Volunteers
- 450 people
- Sponsor
- Celgene
Multiple Myeloma
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma.
- Trial name
- NCT05137054
- Testing
- Linvoseltamab, Daratumumab, Carfilzomib
- Where
- 42 sites in United States, France and 3 more
- Volunteers
- 317 people
- Sponsor
- Regeneron Pharmaceuticals